Vertex Pharmaceuticals Incorporated (OQ:VRTX)
Business Focus: Bio Therapeutic Drugs
| Sector: Healthcare | Industry: Biotechnology & Medical Research |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 50 Northern Avenue BOSTON MA 02210 |
| Tel: | N/A |
| Website: | https://www.vrtx.com |
| IR: | See website |
| Key People | ||
| Jeffrey M. Leiden Executive Chairman of the Board | Joy Liu Corporate Secretary | Reshma Kewalramani President, Chief Executive Officer, Director |
| Charles F. Wagner Chief Financial Officer, Executive Vice President | Stuart A. Arbuckle Chief Operating Officer, Executive Vice President | David M. Altshuler Executive Vice President - Global Research, Chief Scientific Officer |
| Carmen Bozic Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | Amit K. Sachdev Executive Vice President, Chief Patient and External Affairs Officer | Ourania Tatsis Executive Vice President, Chief Regulatory and Quality Officer | Kristen Ambrose Senior Vice President, Chief Accounting Officer |
| Business Overview |
| Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on investing in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has four approved medicines that treat the underlying cause of cystic fibrosis (CF), and one approved therapy that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT). Its pipeline includes clinical-stage programs in CF, SCD, TDT, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Its marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). It is developing non-autologous (allogeneic) fully differentiated, stem-cell derived islet cell therapies designed to replace insulin-producing islet cells that are destroyed in people with T1D. |
| Financial Overview |
| For the three months ended 31 March 2024, Vertex Pharmaceuticals Incorporated revenues increased 13% to $2.69B. Net income increased 57% to $1.1B. Revenues reflect TRIKAFTA segment increase of 18% to $2.48B, Europe segment increase of 20% to $967.4M, United States segment increase of 8% to $1.52B. Net income benefited from Research & Development Expense decrease of 78% to $76.8M (expense), Interest income increase of 48% to $181.2M (income). |
| Employees: | 5,400 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $99,394M as of Mar 31, 2024 |
| Annual revenue (TTM): | $10,185M as of Mar 31, 2024 |
| EBITDA (TTM): | $4,389M as of Mar 31, 2024 |
| Net annual income (TTM): | $4,019M as of Mar 31, 2024 |
| Free cash flow (TTM): | $3,479M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 258,053,387 as of Apr 30, 2024 |
| Index Membership: | S&P 500 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.